Phase I trial investigating the tolerabilty of AE 37 in patients with prostate cancer

Trial Profile

Phase I trial investigating the tolerabilty of AE 37 in patients with prostate cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2015

At a glance

  • Drugs AE 37 (Primary) ; Granulocyte colony-stimulating factors
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 31 May 2013 Data was published in conjunction with the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Generex Biotechnology Corporation media release.
    • 14 Jun 2012 Results have been presented at ASCO-2012 according to a Generex Biotechnology Corporation media release. Results were also summarised in the media release.
    • 18 May 2010 According to a Generex media release, results from this study are being published in the journal Clinical Cancer Research. The online publication date is 13 May 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top